|
|
|
|
Dr. Sunil Gandhi, Cancer & Blood Disease, 06/30/09
I saw a 55-year-old patient.She was diagnosed with breast cancer. Her cancer does not express hormone receptors (estrogen receptor or progesterone receptor). In addition, it does not express HER 2 (a special gene) receptors. This is...
|
|
|
Launch of Targeted Agents and Increased Use of Maintenance Therapy Will Drive the Non-Small-Cell Lung Cancer D
Emerging Agents from Pfizer, AstraZeneca, GlaxoSmithKline, Bayer/Onyx and Boehringer Ingelheim, and Increased Use of Existing Agents from Eli Lilly and Roche Will Drive Growth, According to a New Report from Decision Resources WALTHAM, Mass....
|
|
|
Global Non-Small Cell Lung Cancer Therapeutics Market to Reach $13.3 Billion by 2015, According to New Report
GIA announces the release of a comprehensive global report on Lung Cancer Therapeutics market.World market for non-small cell lung cancer therapeutics is expected to reach $13.3 billion by 2015 fueled by rising incidence of lung cancer,...
|
|
|
Global Non-Small Cell Lung Cancer Therapeutics Market to Reach $13.3 Billion by 2015, According to New Report
GIA announces the release of a comprehensive global report on Lung Cancer Therapeutics market.World market for non-small cell is expected to reach $13.3 billion by 2015 fueled by rising incidence of lung cancer, improved understanding of...
|
|
|
Global Non-Small Cell Lung Cancer Therapeutics Market to Reach $13.3 Billion by 2015, According to New Report
(PRWeb.com via COMTEX) -- CTHP | Quote | Chart | News | PowerRating -- Lung cancer is one of the most common types of cancers across the world, which not only increases mortality rates but also enhances the financial burden on the society.
|
|
|
Thomas Jefferson University: Jefferson researchers identify critical marker of response to gemcitabine in panc
Today's Medical & Research News Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating...
|
|
|
ASCO study: Use of off-label drugs in breast cancer quite common
Researchers from Houstons M.D.Anderson Cancer Center evaluted the prevalence and impact of off-label therapies in breast cancer and found that nearly 35% of women were treated with off-label chemotherapy at some point during their care.
|
|
|
Gemzar Added to Chemoradiation Improves Survival in Locally Advanced Cervical Cancer
_ Gemzar Added to Chemoradiation Improves Survival in Locally Advanced Cervical Cancer.
|
|
|
Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer
The protein, called Hu antigen R (HuR), is a stress response protein found in the cytoplasm of pancreatic tumor cells.In certain experimental settings, pancreatic cancer cells that overexpressed HuR were up to 30-fold more sensitive to...
|
|
|
Critical Marker Of Response To Gemcitabine In Pancreatic Cancer Identified
A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at Thomas Jefferson University.The protein...
|
|
|
Epistem Presents Further Data Supporting its Plucked Hair Biomarker technology at the Institute of Cancer Rese
Data on the effects of Gemcitabine on epithelial tissue released MANCHESTER, England, June 3, 2009- Epistem plc (LSE: EHP), the UK biotechnology and contract research company, will present preclinical results from its recently completed...
|
|
|
Critical Marker Of Response To Gemcitabine In Pancreatic Cancer Identified By Jefferson Researchers
Critical Marker Of Response To Gemcitabine In Pancreatic Identified By Jefferson Researchers Medical Medical Medical Worldwide Search / Oncology hip Funny Useful Websites details of 26,000 UK specialists medical software Ask a Doctor and...
|
|
|
Critical Marker Of Response To Gemcitabine In Pancreatic Cancer Identified By Jefferson Researchers
A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at Thomas Jefferson University.The protein...
|
|
|
Phase III trial of Lilly's Gemzar shows improved progression-free survival in cervical cancer patients
Eli Lilly and Company announced that phase-III trial data showed the addition of Lilly's Gemzar (gemcitabine HCl for injection) to the current standard of care provided a statistically significant increase in progression-free survival...
|
|
|
Researchers Identify Critical Marker of Response to Gemcitabine in Pancreatic Cancer
Newswise A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at.The protein, called Hu antigen...
|
|
|
Discovery of critical marker of response to gemcitabine in pancreatic cancer
A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at Thomas Jefferson University.The protein...
|
|
|
ASCO: Gemzar plus chemoradiation improves cervical cancer survival rates
Adding the chemotherapy drug gemcitabine (Gemzar) to cisplatin chemotherapy and radiation therapy extends overall survival among women with locally advanced cervical cancer, despite increased but tolerable toxicities, according to...
|
|
|
Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer
(PHILADELPHIA) A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by researchers at Thomas Jefferson University...
|
|
|
Critical Gemcitabine Marker In Pancreatic Cancer Identified
Home Cancer Treatment All About: Posted under: A protein related to aggressive cancers can actually improve the efficacy of gemcitabine at treating pancreatic cancer, according to a Priority Report in Cancer Research, published by...
|
|
|
ASCO: New Regimen Shows Promise in Advanced Renal Cell Carcinoma
ORLANDO, June 3 -- Patients with metastatic renal cell carcinoma had encouraging progression-free survival with first-line therapy that included an angiogenesis inhibitor and metronomic chemotherapy, a small study showed.A total of 40...
|
|
|
Epistem to present preclinical results from plucked hair biomarker study
- UK-based biotechnology and contract research company Epistem plc (LON: EHP) announced yesterday (2 June) that it will present preclinical results from its recently completed plucked hair biomarker study at the Institute of Cancer Research...
|
|
|
MedImmune Bags Contract From HHS To Manufacture Laiv For Novel Influenza A (H1n1)
MedImmune has bagged a contract from the US Department of Health and Human Services (HHS), to manufacture monovalent (single-strain) live attenuated influenza vaccine for Novel Influenza A (H1N1).The drug will be used to vaccinate...
|
|
|
Ironwood, Forest's Additional Analysis Reveals Expected Outcome
Ironwood and Forest Laboratories have announced positive results from additional analysis of their phase II(b) study assessing the safety and efficacy of the new, first in class agent linaclotide, in 419 patients with irritable bowel...
|
|
|
Epistem plc to present additional data for its technology at the Institute of Cancer Research Centenary Confer
Epistem plc (LSE: EHP), a biotechnology and contract research company, declared today (2 June) that at the Institute of Cancer Research Centenary Conference, in Queen Elizabeth II Conference Centre, London, UK from 8 to 10 June 2009, it will...
|
|
|
Eli Lilly Reports Progress With Cancer Drug
Indianapolis-based Eli Lilly and Co.'s (NYSE: LLY) cervical cancer drug GEMZAR has concluded a Phase III trial with positive results.The global study found 74 percent of patients given GEMZAR with the standard treatment showed...
|
